Pulse Biosciences filings document regulatory disclosures for a Delaware medical technology company developing nPulse nanosecond pulsed field ablation technology. Its 8-K reports cover clinical and Regulation FD disclosures for the nPulse Cardiac Catheter System, atrial fibrillation study updates, investor presentation materials, and development priorities in electrophysiology, cardiac surgery, and soft tissue ablation.
The company's SEC record also includes proxy materials on board governance, executive compensation, equity awards, and shareholder voting matters. Other filings address capital structure, common stock financing arrangements, officer appointments, compensatory arrangements, operating and financial results, ownership matters, and risk factors tied to its technology development and clinical regulatory activities.
PULSE BIOSCIENCES, INC. director Maria Sainz reported receiving two grants of stock options on June 11, 2026. The awards cover 3,793 and 30,000 options to buy common stock at an exercise price of $26.89 per share and expire on June 11, 2036.
According to the disclosures, 3,793 options vest in equal monthly installments over one year starting July 11, 2026, while 30,000 options vest in equal quarterly installments over one year starting September 5, 2026. These are compensation-related grants, not open‑market stock purchases or sales.
Pulse Biosciences, Inc. reported the results of its 2026 Annual Meeting of Stockholders, held virtually via live audio webcast on June 11, 2026. Stockholders voted on director elections and auditor ratification.
All seven director nominees, including Robert W. Duggan, Paul A. LaViolette, Maria Sainz, Manmeet S. Soni, Darrin R. Uecker, Richard A. van den Broek, and Mahkam Zanganeh, D.D.S., were elected to serve until the 2027 Annual Meeting and until their successors are duly elected and qualified. Support levels were high, with each nominee receiving more than 33.5 million votes “For” and relatively few votes “Against” or “Abstained,” alongside 10,974,550 broker non-votes.
Stockholders also ratified the appointment of Deloitte & Touche LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 45,976,355 votes “For,” 8,265 “Against,” and 17,074 “Abstained.” This confirms both the company’s board composition for the coming year and its choice of external auditor.
Pulse Biosciences plans to redeem its remaining common stock “200% Warrants” issued in the July 3, 2024 rights offering. Holders may exercise these warrants at $11.00 per share until 5:00 p.m. Eastern on July 13, 2026, after which any unexercised warrants will be redeemed for $0.01 per warrant share and then become void.
The company’s right to redeem was triggered because its common stock’s volume weighted average price exceeded $22.00 for 20 consecutive trading days, with an average VWAP of $25.17 over that period. Pulse Biosciences reports it has already raised $60 million in gross proceeds from the rights offering and a further $63.7 million from warrant exercises, and it may receive an additional $2.1 million if all remaining 200% Warrants are exercised before the redemption deadline.
PULSE BIOSCIENCES, INC. director and major shareholder Robert W. Duggan reported an open-market purchase of 660,233 shares of common stock at $19.69 per share. After this purchase, he directly owns 48,370,047 common shares.
He also has indirect holdings of 630,109 shares through Genius 24C Inc. and 450,189 shares through Blazon Corporation, where he is the sole shareholder. The shares were acquired through the company’s at-the-market equity offering program under an Equity Distribution Agreement with TD Securities (USA) LLC and include approximately 700 shares that were previously omitted from a Schedule 14A.
Pulse Biosciences reported a net loss of $18.6M for the three months ended March 31, 2026, compared with $16.8M a year earlier, as it continues to invest heavily in its cardiac and soft-tissue ablation programs. Product revenue reached $0.4M, reflecting initial commercial sales of the Vybrance Percutaneous Electrode System.
Research and development expenses rose to $12.6M, while selling, general and administrative costs were $6.6M. Operating activities used $14.6M of cash. Cash and cash equivalents were $68.3M as of March 31, 2026, with an accumulated deficit of $481.9M.
The company initiated a 2026 strategic realignment to prioritize nsPFA electrophysiology catheters and cardiac devices for atrial fibrillation, reducing near-term spend on cardiac surgery market development and Vybrance sales and marketing. After quarter-end, it raised approximately $12.9M via an at-the-market share sale to its majority stockholder and CEO, and believes current resources and these proceeds can fund operations for at least one year past the financial statement issuance date.
Robert W. Duggan filed Amendment No. 17 to his Schedule 13D on Pulse Biosciences, Inc., reporting beneficial ownership of 49,706,423 shares of common stock, or 71.9% of the outstanding class.
The filing shows Duggan’s holdings include 256,078 options exercisable within 60 days, 630,109 shares held by Genius 24C Inc, and 450,189 shares held by Blazon Corporation, over which he may be deemed a beneficial owner. During the past 60 days, he purchased 660,233 shares at $19.69 per share through the company’s at-the-market equity offering program, funded with personal and entity working capital.
PULSE BIOSCIENCES, INC. director and Chief Executive Officer Paul A. LAVIOLETTE bought 15,000 shares of common stock in an open-market purchase on May 11, 2026 at $19.69 per share. After this transaction, he directly owns 15,846 shares of the company’s stock.
Footnotes explain the shares were acquired through the company’s at-the-market equity offering program under an Equity Distribution Agreement with TD Securities (USA) LLC, during an open trading window under the insider trading policy. His holdings also include shares purchased through the company’s Employee Stock Purchase Plan in March 2026.
PULSE BIOSCIENCES, INC. Chief Executive Officer Paul A. Laviollette purchased 15,000 shares of the company’s common stock in an open-market transaction. The shares were bought at a price of $19.69 per share and are held directly, bringing his direct ownership to 15,000 shares.
According to the disclosure, the shares were acquired through the company’s at-the-market equity offering program under an Equity Distribution Agreement with TD Securities (USA) LLC. The purchases occurred during an open trading window and in line with the company’s Insider Trading Policy and applicable securities laws.
PULSE BIOSCIENCES, INC. director and more than 10% owner Robert W. Duggan bought 660,233 shares of common stock in an open-market purchase at $19.69 per share. After this transaction, he directly owns 48,211,433 shares, with additional indirect holdings of 450,189 shares via Genius 24C Inc. and 630,109 shares via Blazon Corporation. The shares were acquired through the company’s at-the-market equity offering program under an Equity Distribution Agreement with TD Securities (USA) LLC and were purchased during an open trading window in line with the company’s insider trading policy.
Pulse Biosciences, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 11, 2026, at 11:00 a.m. Eastern Time. The agenda includes electing seven directors to serve until the 2027 meeting and ratifying Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026.
The record date is April 28, 2026, with one vote per common share and a majority of outstanding shares required for a quorum. Robert W. Duggan beneficially owns 49,037,818 shares, or 71.6% of the common stock as of March 31, 2026. The proxy details board structure, committee membership, director compensation, equity incentive and inducement plans, a tightened insider trading policy, and related‑party financings, including a 2024 rights offering that raised $60 million.